Biophytis S.A.
Index- P/E- EPS (ttm)-2.61 Insider Own- Shs Outstand12.59M Perf Week8.82%
Market Cap17.85M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month12.69%
Income-31.10M PEG- EPS next Q- Inst Own1.00% Short Float- Perf Quarter-12.60%
Sales- P/S- EPS this Y37.90% Inst Trans-23.36% Short Ratio0.28 Perf Half Y-76.43%
Book/sh0.45 P/B2.47 EPS next Y- ROA-105.90% Target Price15.00 Perf Year-91.46%
Cash/sh1.55 P/C0.71 EPS next 5Y- ROE- 52W Range0.81 - 9.59 Perf YTD-79.21%
Dividend- P/FCF- EPS past 5Y27.10% ROI- 52W High-90.20% Beta-
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin- 52W Low16.04% ATR0.14
Employees22 Current Ratio1.40 Sales Q/Q- Oper. Margin- RSI (14)45.10 Volatility13.23% 13.89%
OptionableNo Debt/Eq2.68 EPS Q/Q61.60% Profit Margin- Rel Volume10.19 Prev Close1.11
ShortableYes LT Debt/Eq1.11 Earnings- Payout- Avg Volume162.63K Price0.94
Recom2.00 SMA20-10.15% SMA50-6.94% SMA200-71.52% Volume268,648 Change-15.32%
Sep-07-22 07:05AM  
Jun-30-22 05:20PM  
Jun-27-22 05:45PM  
Jun-22-22 05:30PM  
Jun-03-22 05:20PM  
May-12-22 02:20AM  
Apr-19-22 02:20AM  
Apr-07-22 08:11AM  
Apr-05-22 05:30PM  
Mar-16-22 03:20AM  
Feb-03-22 09:03AM  
Dec-22-21 05:20PM  
Dec-16-21 02:30AM  
Nov-22-21 05:20PM  
Nov-15-21 03:08PM  
Oct-29-21 02:55AM  
Oct-06-21 05:00PM  
Oct-04-21 05:00PM  
Sep-29-21 02:00AM  
Sep-17-21 02:00AM  
Sep-15-21 02:00AM  
Sep-14-21 02:00AM  
Sep-09-21 02:00AM  
Aug-16-21 08:36AM  
Aug-13-21 05:00PM  
Aug-02-21 06:24AM  
Jul-19-21 05:00PM  
Jul-12-21 12:53PM  
Jul-08-21 02:00AM  
Jun-30-21 05:00PM  
Jun-18-21 08:00PM  
May-12-21 02:00AM  
May-11-21 02:00AM  
Apr-30-21 02:00AM  
Apr-29-21 02:00AM  
Apr-27-21 02:00AM  
Apr-26-21 02:00AM  
Apr-13-21 05:00PM  
Mar-22-21 03:00AM  
Mar-19-21 06:00PM  
Mar-10-21 10:08PM  
Feb-26-21 02:00AM  
Feb-17-21 02:00AM  
Feb-15-21 02:00AM  
Feb-10-21 09:16AM  
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.